FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MCLAUGHLIN KEVIN F		 2. Issuer Name and Ticker or Trading Symbol

ACCELERON PHARMA INC [ XLRN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP, CFO and Treasurer
(Last)          (First)          (Middle)

128 SIDNEY STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

12/14/2020
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/14/2020  M(1)  7252 A$41.20 18468 D  
Common Stock 12/14/2020  M(1)  7700 A$27.97 26168 D  
Common Stock 12/14/2020  M(1)  24986 A$30.17 51154 D  
Common Stock 12/14/2020  M(1)  2590 A$40.61 53744 D  
Common Stock 12/14/2020  S(1)  42528 D$130.14 11216 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock $41.20 12/14/2020  M (1)    7252   (2)1/8/2025 Common Stock 7252 $0 0 D  
Option to Purchase Common Stock $27.97 12/14/2020  M (1)    7700   (3)3/3/2026 Common Stock 7700 $0 0 D  
Option to Purchase Common Stock $30.17 12/14/2020  M (1)    24986   (4)3/2/2027 Common Stock 24986 $0 5163 D  
Option to Purchase Common Stock $40.61 12/14/2020  M (1)    2590   (5)3/1/2028 Common Stock 2590 $0 26262 D  
Explanation of Responses:
(1) The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
(2) The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after the grant.
(3) The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016.
(4) The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017.
(5) The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
MCLAUGHLIN KEVIN F
128 SIDNEY STREET
CAMBRIDGE, MA 02139

SVP, CFO and Treasurer
Signatures
/s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin12/15/2020
**Signature of Reporting PersonDate
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.